Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019



Summary



GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Osteoarthritis Pain Therapeutics market. The report identifies the key trends shaping and driving the global Osteoarthritis Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Osteoarthritis Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.



Scope


The report provides information on the key drivers and challenges of the Osteoarthritis Pain Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Osteoarthritis Pain Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Osteoarthritis Pain Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Osteoarthritis Pain Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Osteoarthritis Pain Therapeutics market



Reasons to buy


The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Osteoarthritis Pain Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Osteoarthritis Pain Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Osteoarthritis Pain Therapeutics market landscape? – Identify, understand and capitalize.

Table Of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Osteoarthritis Pain Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Classification of Osteoarthritis 8
2.1.2 Types of Osteoarthritis 8
2.1.3 Osteoarthritis Pain 13
2.2 Epidemiology 13
2.2.1 Prevalence 13
2.3 Quality of Life 14
2.4 Etiology 14
2.5 Signs and Symptoms 16
2.6 Diagnosis 16
2.6.1 Physical Examination 16
2.6.2 Radiological Examination 17
2.6.3 Laboratory Test 18
2.7 Pathophysiology 19
2.7.1 Progression of the Disease 19
2.8 Treatment and Management Options 20
2.8.1 Pharmacological treatment 24
2.9 Referral Pathway 27
2.10 GlobalData Pipeline Report Guidance 29
3 Osteoarthritis Pain Therapeutics - Market Characterization 30
3.1 Overview 30
3.2 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Global 31
3.3 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Global 32
3.4 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - The US 33
3.5 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - The US 34
3.6 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - France 35
3.7 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - France 36
3.8 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Germany 37
3.9 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Germany 38
3.10 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Italy 39
3.11 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Italy 40
3.12 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Spain 41
3.13 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Spain 42
3.14 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - The UK 43
3.15 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - The UK 44
3.16 Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Japan 45
3.17 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Japan 46
3.18 Drivers and Barriers for the Osteoarthritis Pain Therapeutics Market 47
3.18.1 Drivers for the Osteoarthritis Pain Therapeutics Market 47
3.18.2 Barriers for the Osteoarthritis Pain Therapeutics Market 48
3.19 Opportunity and Unmet Need Analysis 49
3.20 Key Takeaway 50
4 Osteoarthritis Pain Therapeutics - Competitive Assessment 51
4.1 Overview 51
4.2 Strategic Competitor Assessment 51
4.3 Product Profiles for the Major Marketed Products in the Osteoarthritis Pain Therapeutics Market 53
4.3.1 Celebrex (celecoxib) 53
4.3.2 Voltaren Gel (diclofenac sodium) 53
4.3.3 Hyalgan (sodium hyaluronate) 54
4.3.4 Cymbalta (duloxetine) 54
4.3.5 Synvisc (hylan G-F 20) 55
4.4 Key Takeaway 56
5 Osteoarthritis Pain Therapeutics - Pipeline Assessment 57
5.1 Overview 57
5.2 Strategic Pipeline Assessment 57
5.3 Osteoarthritis Pain Therapeutics Pipeline - Pipeline by Phases of Development 58
5.3.1 Osteoarthritis Pain Therapeutics - Regulatory Filed Products 58
5.3.2 Osteoarthritis Pain Therapeutics - Phase III Pipeline 59
5.3.3 Osteoarthritis Pain Therapeutics - Phase II/III Pipeline 59
5.3.4 Osteoarthritis Pain Therapeutics - Phase II Pipeline 60
5.3.5 Osteoarthritis Pain Therapeutics - Phase I/II Pipeline 60
5.3.6 Osteoarthritis Pain Therapeutics - Phase I Pipeline 61
5.3.7 Osteoarthritis Pain Market - Discovery and Pre-Clinical Pipeline 61
5.3.8 Technology Trends Analytic Framework 62
5.4 Osteoarthritis Pain Therapeutics Market -Pipeline by Mechanism of Action 64
5.5 Molecule Profile for Promising Drugs Under Development 65
5.5.1 2 PX 65
5.5.2 Civanex 66
5.5.3 BEMA 67
5.5.4 CEP-33237 67
5.6 Key Takeaway 67
6 Osteoarthritis Pain Therapeutics - Clinical Trials Mapping 68
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 68
6.2 Clinical Trials by Phase 69
6.3 Clinical Trials by Trial Status 70
6.4 Prominent Sponsors 71
6.5 Top Companies Participating in OA Pain Therapeutics Clinical Trials 73
7 Strategic Assessment 74
7.1 Key Events Impacting the Future Market 74
7.2 Osteoarthritis Pain Therapeutics: Implications for Future Market Competition 75
8 Osteoarthritis Pain Therapeutics - Future Players 76
8.1 Introduction 76
8.2 Company Profiles 77
8.2.1 Winston Pharmaceuticals, Inc. 77
8.2.2 Teva Pharmaceuticals 77
8.2.3 Pfizer, Inc. 79
8.2.4 SantoSolvo AS 81
8.2.5 BioDelivery Sciences International, Inc. 82
8.2.6 Savient Pharmaceuticals, Inc. 83
8.2.7 Eli Lilly and Company 84
8.2.8 Horizon Pharma 85
8.2.9 Boehringer Ingelheim 85
9 Osteoarthritis Pain Therapeutics - Licensing and Partnership Deals 87
10 Osteoarthritis Pain Therapeutics - Appendix 88
10.1 Market Definitions 88
10.2 Abbreviations 88
10.3 Bibliography 89
10.4 Methodology 91
10.4.1 Coverage 91
10.4.2 Secondary Research 91
10.4.3 Forecasting 92
10.4.4 Primary Research 94
10.4.5 Expert Panel Validation 95
10.5 Contact Us 95
10.6 Disclaimer 95

List of Tables

Table 1: Prevalence rates of Osteoarthritis Pain by Country/Region 13
Table 2: Prevalence Pool of Osteoarthritis Pain Patients in Seven Major Markets 14
Table 3: Clinical Features of Osteoarthritis Pain 16
Table 4: Classification Criteria for Osteoarthritis Pain 18
Table 5: Treatment Options for Osteoarthritis Pain 23
Table 6: Osteoarthritis Pain Therapeutics Market, Global, Revenue ($m), 2006-2011 31
Table 7: Osteoarthritis Pain Therapeutics Market, Global, Forecast ($m), 2011-2019 32
Table 8: Osteoarthritis Pain Therapeutics Market, The US, Revenue ($m), 2006-2011 33
Table 9: Osteoarthritis Pain Therapeutics Market, The US, Forecast ($m), 2011-2019 34
Table 10: Osteoarthritis Pain Therapeutics Market, France, Revenue ($m), 2006-2011 35
Table 11: Osteoarthritis Pain Therapeutics Market, France, Forecast ($m), 2011-2019 36
Table 12: Osteoarthritis Pain Therapeutics Market, Germany, Revenue ($m), 2006-2011 37
Table 13: Osteoarthritis Pain Therapeutics Market, Germany, Forecast ($m), 2011-2019 38
Table 14: Osteoarthritis Pain Therapeutics Market, Italy, Revenue ($m), 2006-2011 39
Table 15: Osteoarthritis Pain Therapeutics Market, Italy, Forecast ($m), 2011-2019 40
Table 16: Osteoarthritis Pain Therapeutics Market, Spain, Revenue ($m), 2006-2011 41
Table 17: Osteoarthritis Pain Therapeutics Market, Spain, Forecast ($m), 2011-2019 42
Table 18: Osteoarthritis Pain Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
Table 19: Osteoarthritis Pain Therapeutics Market, The UK, Forecasts ($m), 2011-2019 44
Table 20: Osteoarthritis Pain Therapeutics Market, Japan, Revenue ($m), 2006-2011 45
Table 21: Osteoarthritis Pain Therapeutics Market, Japan, Forecasts ($m), 2011-2019 46
Table 22: Primary Efficacy Results for Synvisc: WOMAC Pain Score 55
Table 23: Adverse Events Associated with Synvisc 56
Table 24: Osteoarthritis Pain Therapeutics - Regulatory Filed Products, 2012 58
Table 25: Osteoarthritis Pain Therapeutics - Phase III Pipeline, 2012 59
Table 26: Osteoarthritis Pain Therapeutics - Phase II/III Pipeline, 2012 59
Table 27: Osteoarthritis Pain Therapeutics - Phase II Pipeline, 2012 60
Table 28: Osteoarthritis Pain Therapeutics - Phase I/II Pipeline, 2012 60
Table 29: Osteoarthritis Pain Therapeutics - Phase I Pipeline, 2012 61
Table 30: Osteoarthritis Pain Therapeutics - Preclinical and Discovery Phase Pipeline, 2012 61
Table 31: Osteoarthritis Pain Therapeutics - Clinical Trials by Country, 2012 68
Table 32: Osteoarthritis Pain Therapeutics - Clinical Trials by Phase, 2012 69
Table 33: Osteoarthritis Pain Therapeutics - Clinical Trials by Status, 2012 70
Table 34: Osteoarthritis Pain Therapeutics, Overall Sponsors, 2012 71
Table 35: Osteoarthritis Pain Therapeutics, Most Prominent Sponsors, 2012 72
Table 36: Osteoarthritis Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2012 73
Table 37: Winston Pharmaceuticals, Inc. Osteoarthritis Pain Pipeline, 2012 77
Table 38: Osteoarthritis Pain Therapeutics, Cephalon Inc./Teva Pharmaceuticals, Osteoarthritis Pain Therapeutics Pipeline, 2012 79
Table 39: Pfizer, Osteoarthritis Pain Pipeline, 2011 81
Table 40: Osteoarthritis Pain Therapeutics, SantoSolve Pain Management Pipeline, 2012 81
Table 41: Osteoarthritis Pain Therapeutics, BioDelivery Sciences Pain Management Pipeline, 2012 83
Table 42: Licensing and Partnership Deals, 2008-2011 87

List of Figures

Figure 1: Differentiation between Normal Joint and Osteoarthritis Joint 7
Figure 2: Types of Osteoarthritis Pain 8
Figure 3: Knee Osteoarthritis 9
Figure 4: Osteoarthritis of Hand, Heberden’s Nodes and Bouchard’s Nodes 9
Figure 5: Hip Osteoarthritis 10
Figure 6: Examples of Disc Problems which Lead to Spine Osteoarthritis 11
Figure 7: Joints and Bones of the Foot and Ankle 12
Figure 8: Factors Affecting Degeneration of Cartilage 15
Figure 9: Key Opinion Leader Insights, Diagnosis of Osteoarthritis Pain in the US and the UK. 16
Figure 10: Progression of Osteoarthritis Pain Disease 20
Figure 11: Key Opinion Leader Insights, Guidelines for Osteoarthritis Pain in the US and the UK 21
Figure 12: Summary of Treatment Options for Osteoarthritis Pain 21
Figure 13: Key Opinion Leader Insights, Treatment of Osteoarthritis Pain in the US and the UK 22
Figure 14: Key Opinion Leader Insights, Pharmacological Treatment for Osteoarthritis Pain in the US and the UK 25
Figure 15: Management of Osteoarthritis of the Knee 26
Figure 16: Management of Osteoarthritis of the Hip 27
Figure 17: Referral Pathway for Osteoarthritis Pain 27
Figure 18: Key Opinion Leader Insights, Referral Pathway for Osteoarthritis Pain in the US and the UK 28
Figure 19: Osteoarthritis Pain Therapeutics Market, Global, Revenue ($m), 2006-2011 31
Figure 20: Osteoarthritis Pain Therapeutics Market, Global, Forecast ($m), 2011-2019 32
Figure 21: Osteoarthritis Pain Therapeutics Market, The US, Revenue ($m), 2006-2011 33
Figure 22: Osteoarthritis Pain Therapeutics Market, The US, Forecast ($m), 2011-2019 34
Figure 23: Osteoarthritis Pain Therapeutics Market, France, Revenue ($m), 2006-2011 35
Figure 24: Osteoarthritis Pain Therapeutics Market, France, Forecast ($m), 2011-2019 36
Figure 25: Osteoarthritis Pain Therapeutics Market, Germany , Revenue ($m), 2006-2011 37
Figure 26: Osteoarthritis Pain Therapeutics Market, Germany, Forecast ($m), 2011-2019 38
Figure 27: Osteoarthritis Pain Therapeutics Market, Italy, Revenue ($m), 2006-2011 39
Figure 28: Osteoarthritis Pain Therapeutics Market, Italy, Forecast ($m), 2011-2019 40
Figure 29: Osteoarthritis Pain Therapeutics Market, Spain, Revenue ($m), 2006-2011 41
Figure 30: Osteoarthritis Pain Therapeutics Market, Spain, Forecast ($m), 2011-2019 42
Figure 31: Osteoarthritis Pain Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
Figure 32: Osteoarthritis Pain Therapeutics Market, The UK, Forecast ($m), 2011-2019 44
Figure 33: Osteoarthritis Pain Therapeutics Market, Japan, Revenue ($m), 2006-2011 45
Figure 34: Osteoarthritis Pain Therapeutics Market, Japan, Forecast ($m), 2011-2019 46
Figure 35: Key Opinion Leader Insights, Current Unmet Need for Osteoarthritis Pain in the US and the UK 49
Figure 36: Opportunity and Unmet Need in the Osteoarthritis Pain Therapeutics Market, 2011 50
Figure 37: Key Opinion Leader Insights, Limitations with the Currently Available Treatment Options for Osteoarthritis Pain in the US and the UK 51
Figure 38: Osteoarthritis Pain Therapeutics - Strategic Competitor Assessment, 2011 52
Figure 39: Key Opinion Leader Insights, Research for Future Treatment Options for Osteoarthritis Pain in the US and the UK 57
Figure 40: Osteoarthritis Pain Therapeutics - Pipeline by Phase of Development, 2012 58
Figure 41: Osteoarthritis Pain Therapeutics - Technology Trends Analytics Framework, 2012 62
Figure 42: Osteoarthritis Pain Therapeutics - Technology Trends Analytics Framework - Description, 2012 63
Figure 43: Osteoarthritis Pain Therapeutics - Pipeline by Mechanism of Action, 2012 64
Figure 44: Key Opinion Leader Insights, Target Profile Testing for Osteoarthritis Pain in the US and the UK 65
Figure 45: Osteoarthritis Pain Therapeutics - Clinical Trials by Country, 2012 68
Figure 46: Osteoarthritis Pain Therapeutics - Clinical Trials by Phase, 2012 69
Figure 47: Osteoarthritis Pain Therapeutics - Clinical Trials by Status, 2012 70
Figure 48: Osteoarthritis Pain Therapeutics - Overall Sponsors, 2012 71
Figure 49: Osteoarthritis Pain Therapeutics - Prominent Sponsors, 2012 72
Figure 50: Osteoarthritis Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2012 73
Figure 51: Osteoarthritis Pain Therapeutics Market, Drivers and Barriers 2011 74
Figure 52: Implications for Future Market Competition in the Osteoarthritis Pain Market, 2011 75
Figure 53: Osteoarthritis Pain Therapeutics Market - Pipeline by Company, 2012 76

Companies mentioned
Winston Pharmaceuticals, Inc.
Teva Pharmaceuticals
Pfizer, Inc.
SantoSolvo AS
BioDelivery Sciences International, Inc.
Savient Pharmaceuticals, Inc.
Eli Lilly and Company
Horizon Pharma
Boehringer Ingelheim

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Sarepta Therapeutics, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.